Biological effects of Goal Directed Therapy in surgical patients - Biological effects of Goal Directed Therapy in surgical patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-004160-32-GB

Enrollment

Unknown

Registered

2006-09-29

Start date

2006-11-15

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative complications in patients who undergo major surgery

Interventions

Trade Name: Dopacard Pharmaceutical Form: Intravenous infusion INN or Proposed INN: DOPEXAMINE CAS Number: 86197479 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult patients admitted to a critical care unit following elective major abdominal surgery within Barts and the London NHS Trust will be eligible for recruitment. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Refusal of consent, concurrent lithium therapy, acute myocardial ischaemia and acute arrhythmias.

Design outcomes

Primary

Measure	Time frame
Main Objective: To demonstrate a reduction in post-operative complication rates associated with the use of goal-directed therapy (incorporating dopexamine infusion).;Secondary Objective: 1. To demonstrate an improvement in microvascular perfusion associated with the use of goal-directed therapy (incorporating dopexamine infusion). 2. To demonstrate an improvement in tissue oxygenation associated with the use of goal-directed therapy (incorporating dopexamine infusion). 3. To demonstrate a reduction in post-operative duration of hospital stay associated with the use of goal-directed therapy (incorporating dopexamine infusion). 4. To demonstrate a reduction in 28 day mortality associated with the use of goal-directed therapy (incorporating dopexamine infusion). ;Primary end point(s): Reduction in 28 day post-operative complication rates associated with the use of Goal directed therapy (incorporating dopexamine infusion)	—

Measure

Time frame

Main Objective: To demonstrate a reduction in post-operative complication rates associated with the use of goal-directed therapy (incorporating dopexamine infusion).;Secondary Objective: 1. To demonstrate an improvement in microvascular perfusion associated with the use of goal-directed therapy (incorporating dopexamine infusion). 2. To demonstrate an improvement in tissue oxygenation associated with the use of goal-directed therapy (incorporating dopexamine infusion). 3. To demonstrate a reduction in post-operative duration of hospital stay associated with the use of goal-directed therapy (incorporating dopexamine infusion). 4. To demonstrate a reduction in 28 day mortality associated with the use of goal-directed therapy (incorporating dopexamine infusion). ;Primary end point(s): Reduction in 28 day post-operative complication rates associated with the use of Goal directed therapy (incorporating dopexamine infusion)

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026